October 29, 2025
Immutep Quarterly Activities Report Q1 FY26
October 20, 2025
Primary Endpoint Met in EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma and Data Presented at ESMO Congress 2025
Two Posters at ESMO Congress 2025 Highlight Immutep’s Focus on Changing Treatment Landscape in First Line Non-Small Cell Lung Cancer
October 13, 2025
Immutep Announces Successful Completion of FDA Project Optimus Requirements
October 9, 2025
Immutep Announces Update for TACTI-004 (KEYNOTE-F91) Phase III Trial in First Line Non-Small Cell Lung Cancer
September 22, 2025
Immutep Announces Research Collaboration with the George Washington University Cancer Center to Evaluate Neoadjuvant Efti
April 23, 2025
Investor Update – April 2025
November 26, 2024
Investor Update – November 2024
February 21, 2024
Investor Update – February 2024
Canaccord Genuity – Positive ESMO reads in NSCLC and sarcoma; BUY, A$0.98 PT (Analyst: Elyse Shapiro)
September 23, 2025
Wilsons – Breast Cancer + subq Keytruda thoughts; Maintain Overweight; A$1.20 PT (Analysts Dr Shane Storey and Dr Lisa Worley)
September 10, 2025
Wilsons – NSCLC unfazed. Bispecifics fade at WCLC. Maintain Overweight; A$1.20 PT (Analysts Dr Shane Storey and Dr Lisa Worley)
August 5, 2025
Maxim – Positive FDA Feedback in 1L H&N Cancer; Sets Stage for Potential Accelerated Path Forward – Rated Buy, US$12 PT (Analyst: Jason McCarthy, Ph.D.)
Canaccord Genuity – Turning Heads: A delineated path forward for efti in HNSCC; Maintain BUY; A$0.98 PT (Analyst: Elyse Shapiro)
July 30, 2025
Baird – FY4Q25: Ongoing Enrollment for Phase 3 1L NSCLC Study; Broad Progress; Rated OP, US$7 PT (Analyst: Colleen M. Kusy, CFA)
Please fill out the registration form below to receive updates and announcements by e-mail.
*Required
I/We authorise you to act in accordance with my/our instructions set out above.
The privacy policy was read and accepted.
